Tocilizumab treatment in COVID‐19: A single center experience

https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25801

In the present study, authors discuss the treatment response of Tocilizumab (TCZ) therapy in COVID‐19 infected patients. The demographic, treatment, laboratory parameters of C‐reactive protein (CRP) and IL‐6 before and after TCZ therapy and clinical outcomes were retrospectively assessed. Totally 15 patients with COVID‐19 were included in this study. Elevated IL‐6 is the indication for TCZ use in COVID‐19. The levels of IL‐6 before TCZ administration ranged from 16.4 to 627.1 pg/mL (2 times to nearly 90 times higher than normal). After starting TCZ therapy, serum IL‐6 level in 10 (66.7%) patients tended to spike shortly in first and then decreased. TCZ appears to be an effective treatment for these critically ill patients with elevated IL‐6, the repeated dose of the TCZ is recommended.

Tags: